Gopinath v. Somalogic, Inc.

District Court, S.D. California·Decided November 22, 2023·No. 3:23-cv-01164·Unknown

Opinion

ASHWIN GOPINATH, Case No.: 3:23-cv-01164-W-WVG an individual, ORDER GRANTING IN PART AND Plaintiff, DENYING IN PART MOTION TO v. DISMISS [Doc. 19] SOMALOGIC, INC., a Delaware, Defendant. SOMALOGIC, INC., a Delaware corporation, Counterclaimant, v. an individual, Counter-Defendant.

Pending before the Court is Dr. Ashwin Gopinath’s (“Counter-Defendant”) motion to dismiss ([Doc. 19], “Motion”) all four of Somalogic, Inc.’s (“Counterclaimant”) counterclaims ([Doc. 17], “Countercomplaint” ). Counterclaimant opposes the Motion ([Doc. 28], “Opposition”). Counter-Defendant has replied. ([Doc. 33], “Reply”.) The Court decides the matter on the papers submitted and without oral argument. See Civ. L.R. 7.1(d)(1). For the reasons stated below, the Court GRANTS IN PART and DENIES IN PART the Motion. This lawsuit arises out of a business merger gone sour. As alleged, Counterclaimant (a biotech company) acquired the San Diego based DNA nanotechnology start-up company Palamedrix, Inc. (“Palamedrix”) in the summer of 2022. (Countercomplaint at ¶¶ 1-2, 17.) Palamedrix was founded by three individuals, Dr. Shane Bowen, Dr. Paul Rothemund, and Counter-Defendant (collectively, the “Founders”). (Id. at ¶ 2.) According to Counterclaimant, it was “primarily interested in acquiring Palamedrix” not because of any property Palamedrix owned, but instead because it wanted to employ its three Founders and “other scientists.” (Id. at ¶ 3.) As such, Counterclaimant executed a merger agreement (the “Merger Agreement”2) with Palamedrix on July 25, 2022, whereby Counterclaimant paid Palamedrix $14 million in cash (“Upfront Cash”) and an additional $21 million worth of Counterclaimant’s common stock (“Upfront Stock”). (Id. at ¶ 19.) As alleged, this consideration was largely divided between Palamedrix’s three Founders and for his part, Counter- Defendant’s share of the Upfront Stock was 456,286 individual shares. (Id. at ¶¶ 20, 33.) Additionally, the Merger Agreement provided that an additional $17.5 million worth of “consideration” may be paid to the three Founders if certain “revenue-based milestones” were met by August of 2027 and August of 2028 and if the Founders remained employed “full-time” by Counterclaimant (the “Milestone Consideration”). (Id. at ¶ 20; Merger

1 The Countercomplaint begins on page 13 of Doc. 17. Agreement at Section 2.16(g)(i).) The Merger Agreement closed on August 31, 2022 (the “Closing Date”). To entice Counter-Defendant to remain with Counterclaimant after the merger, it also entered into a side agreement (the “Founder Side Letter”3) on July 25, 2022 (the same date the Merger Agreement was executed)—which, in relevant part, provided that certain percentages of the Counter-Defendant’s shares of the Upfront Stock Consideration would not vest unless he remained employed with Counterclaimant 12, 24, and 36 months after the Closing Date. (Id. at ¶¶ 22-24, 30.) Specifically, the Founder Side Letter provided that Counter-Defendant would have 76,062.88 shares of the Upfront Stock vest to him on the Closing Date, and would then have an additional 126,756.25 shares of the Upfront Stock vest to him if he remained employed by Counterclaimant every 12 months thereafter for the next three years (i.e. 126,756.25 would vest 12 months after the Closing Date, another 126,756.25 would vest 24 months after the Closing Date, and the final 126,756.25 would vest to him 36 months after the Closing Date). (Id. at ¶¶ 33-34; see Founder Side Letter at Section 2(a)-(c).) If Counter-Defendant was fired for “Cause” or resigned without “Good Reason” before these dates, the outstanding, unvested stock would not vest to him. (Countercomplaint at ¶ 30). “Cause” and “Good Reason” are both defined terms in the Merger Agreement, although not in the Founder Side Letters. (Id. at ¶¶ 31-32.) Similarly, the Counter-Defendant was only eligible to receive the Milestone Consideration if the requisite revenue milestones were met in 2027 and 2028 and he remained employed by Counterclaimant full-time—unless he was fired without “Cause” or resigned with “Good Reason.” (Countercomplaint at ¶ 37-38; Merger Agreement at Section 2.16(g)(i).) According to Counterclaimant, the Founders remaining after the merger was so important that the Merger Agreement specifically identified the Founders signing their Founder Side Letters and accepting employment offers (the “Founder Offer Letter” ) with Counterclaimant as “material inducement” to Counterclaimant executing the Merger Agreement and a “Condition to Closing.” (Id. at ¶ 22; Merger Agreement at 2.) In turn, the Founder Side Letters stated that “[e]ntering into this Side Letter will be a condition precedent to” Counterclaimant “executing the [M]erger [A]greement.” (Id. at ¶ 22; Founder Side Letter at Section 2.) Unfortunately, the relationship between Counterclaimant and Counter-Defendant soured shortly after the merger. Indeed, on November 21, 2022, Counter-Defendant sent Counterclaimant’s attorneys a letter (“Demand Letter”) asserting that he would be well within his rights to resign for “Good Reason” given that certain former Palamedrix employees had left Counterclaimant shortly after the merger. (Countercomplaint at ¶ 77.) Then, on March 14, 2023, Counterclaimant informed Counter-Defendant that he was in violation of numerous company policies and was suspending his access to the company systems and email. (Countercomplaint at ¶ 81.) On April 10, 2023, Counter-Defendant informed Counterclaimant that he was resigning. (Id. at ¶ 84.) Shortly thereafter, on April 28, 2023, Counter-Defendant initiated this case by filing his complaint (“Complaint”5) against Counterclaimant in San Diego County Superior Court, seeking: (1) declaratory judgment that Counter-Defendant resigned for “Good Reason” under the Merger Agreement (thereby entitling him to the rest of his Upfront Stock vesting and his potential share of the Milestone Consideration despite no longer working for Counterclaimant); and (2) that alternatively, he was wrongfully discharged (i.e. without “Cause”) for “refusing to condone and reporting gender discrimination and harassment” at Counterclaimant. (Complaint at ¶¶ 80, 86.)

Free access — add to your briefcase to read the full text and ask questions with AI

Gopinath v. Somalogic, Inc., (S.D. Cal. 2023).

Gopinath v. Somalogic, Inc. (Gopinath v. Somalogic, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Papasan v. Allain
478 U.S. 265 (Supreme Court, 1986)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Robert S. Robertson v. Dean Witter Reynolds, Inc.
749 F.2d 530 (Ninth Circuit, 1984)
D. Neubronner v. Michael R. Milken
6 F.3d 666 (Ninth Circuit, 1993)
Moss v. U.S. Secret Service
572 F.3d 962 (Ninth Circuit, 2009)
Baggett v. Hewlett-Packard Co.
582 F. Supp. 2d 1261 (C.D. California, 2007)
Slivinsky v. Watkins-Johnson Co.
221 Cal. App. 3d 799 (California Court of Appeal, 1990)
Storek & Storek, Inc. v. Citicorp Real Estate, Inc.
122 Cal. Rptr. 2d 267 (California Court of Appeal, 2002)
Guido v. Koopman
1 Cal. App. 4th 837 (California Court of Appeal, 1991)
Falk v. General Motors Corp.
496 F. Supp. 2d 1088 (N.D. California, 2007)
Guz v. Bechtel National, Inc.
8 P.3d 1089 (California Supreme Court, 2000)
Wash. Mut. Bank v. Superior Court of Orange Cty.
15 P.3d 1071 (California Supreme Court, 2001)
Openshaw v. Fedex Ground Package System, Inc.
576 F. App'x 685 (Ninth Circuit, 2014)
Bibiji Kaur Puri v. Sopurkh Kaur Khalsa
674 F. App'x 679 (Ninth Circuit, 2017)
Bevis v. Terrace View Partners, LP
244 Cal. Rptr. 3d 797 (California Court of Appeals, 5th District, 2019)
Sprewell v. Golden State Warriors
266 F.3d 979 (Ninth Circuit, 2001)
Gompper v. Visx, Inc.
298 F.3d 893 (Ninth Circuit, 2002)
Vess v. Ciba-Geigy Corp. USA
317 F.3d 1097 (Ninth Circuit, 2003)